Navigation Links
Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival
Date:12/9/2010

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

Paclitaxel/carboplatin are commonly used chemotherapy drugs in lung cancer patients. Ipilimumab is a human monoclonal antibody that is used to activate the immune system. It works by blinding to and blocking the activity of CTLA-4, a molecule on T-cells that is thought to play a large role in regulating natural immune responses, which as a result sustains an active immune response when attacking cancer cells.

Researchers in this randomized phase II trial sought to determine if adding ipilimumab to treatments for stage IIIb/IV lung cancer patients would impact overall survival and progression free survival. Over 200 patients were treated using ipilimumab plus a concurrent schedule of paclitaxel/carboplatin, ipilimumab plus a phased schedule of paclitaxel/carboplatin or paclitaxel/carboplatin alone.

With both schedules, using ipilimumab in combination with paclitaxel/carboplatin showed improved progression free survival rates when compared to paclitaxel/carboplatin alone. The phased schedule did show better efficacy than the concurrent schedule, but in no instance did ipilimumab increase paclitaxel/carboplatin related toxicity.

"Phase III and IV lung cancers do not often see positive end results, so there is a lot of room to improve treatments for this disease," Thomas Lynch, M.D., lead author of the study, a professor of medicine at Yale University in New Haven, Conn., and director of the Yale Cancer Center, said. "Ipilimumab is one of the few immunotherapies that have shown positive results in treating lung cancers, and if adding this to standard treatments can improve survival, then it is worth further trials."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-431-2332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Alzheimers Association Applauds Social Security Administration for Adding Early-Onset Alzheimers to Its Compassionate Allowances Initiative
2. Adding Surgery to Meds May Improve Life With Parkinsons
3. Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering
4. Adding Recess to the Workday Gains Backers
5. Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival
6. Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances
7. Adding Monounsaturated Fats to Diet May Boost Heart Health
8. Adding monounsaturated fats to a low-cholesterol diet can further improve levels
9. Adding pharmacists to docs offices helps patient outcomes, study shows
10. Adding Surgery to Meds May Help Diabetics With Heart Disease
11. One-third of antimalarial medicines sampled in 3 African nations found to be substandard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... of individuals with HIV because it is not known to have significant interactions ... favorable effects to both lower cholesterol levels and dampen inflammation in the bloodstream. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... that over the last decade, student well-being has seriously declined. "When disenfranchised youth ... formal education, join the Islamic State to turn the historic multi-ethnic and multi-religious ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is proud to ... will be held at 7:30 pm on May 10th at the University Auditorium. , ... Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert will kick ...
(Date:4/23/2017)... ... 23, 2017 , ... Altura Communication Solutions, a nationwide provider ... certification and SMB specialization. Altura is now qualified to sell, install and ... Select Certification, Altura fulfilled the training and exam requirements for the Cisco Small ...
(Date:4/22/2017)... ... April 22, 2017 , ... The San Juan Capistrano summer camp team at the ... the need for summer camps to provide physical activities for all campers. To read the ... Summer Camps , With an increase in specialty camps that focus on what the report ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: